This randomized , open-label , interventional crossover study with an immediate versus deferred use of Niaspan FCT for @ weeks will assess its ability to reduce immune activation and thus increase CD@ recovery in @ HIV-infected individuals with suboptimal immune responses despite sustained virologic suppression .